|   | 
                  
                       | 
                      | 
                    
                        
                            
                                | 
                                  
                                 | 
                             
                             |  
                            
                                
                                    
                                        
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ¿Ã´õ¸¶°Ö  ALLDERMA GEL[Crotamiton , Dexamethasone acetate , Dibucaine HCl , Diphenhydramine HCl , Dl-Camphor , L-menthol]  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |                   
                                        | 
                                             | 
                                         
                            
                                
                            
                            
                              
                                                        
                              
                                                
                            
 |   
    | 
      
     | 
 
 |  
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
  
  
    
      
  
    
       |  
      
        
          
            
                | Çã°¡Á¤º¸ | 
             
           
         | 
       
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
            ºñ±Þ¿©
          
        
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
      [Áúº´ÄÚµåÁ¶È¸]
     
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
   
    | Á¦Ç°¼º»ó | 
    ¹«»öÀÇ Åõ¸íÇÑ °ÖÁ¦  [Á¦ÇüÁ¤º¸ È®ÀÎ] |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    15g | 
   
  
  
  
  
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
  
     
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
     
    
     
	 
      ´ÙÀ½ Áõ»ó ¹× ÁúȯÀÇ ¿ÏÈ : ½ÀÁø, ÇǺο°, Áø¹«¸§, ¶¡¶ì, ¹ßÀû, °¡·Á¿ò, °æÁõÀÇ µ¿»ó, ¹ú·¹ ¹°¸°µ¥, ´ã¸¶Áø 
      
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
      [󹿾à¾î] 
       1ÀÏ 1-¼öȸ, ȯºÎ¿¡ Àû´ç·®À» ¹Ù¸¥´Ù.     
      	
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    - 30°³¿ù ÀÌÇÏÀÇ À¯¾Æ 
 - ¼öµÎ, ¹«Á», ¹é¼± ¶Ç´Â È³ó¼º ÁúȯÀÌ Àִ ȯÀÚ
 
  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    - Áö±Ý±îÁö ¾à°ú ÈÀåǰ¿¡ ´ëÇÑ ¾Ë·¹¸£±â Áõ»ó(¿¹¸¦ µé¾î ¹ßÁø, ¹ßÀû, °¡·Á¿ò Áõ, ¿Ì µî)À» ÀÏÀ¸Å² ÀûÀÌ ÀÖ´Â »ç¶÷ 
 - ½ÀÀ±°ú Áø¹«¸¥ »óó°¡ ½ÉÇÑ »ç¶÷ 
 - ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â »ç¶÷ 
 - ȯºÎ°¡ ±¤¹üÀ§ÇÑ È¯ÀÚ 
 - ¼Ò¾Æ¿¡ Àû¿ë½Ã °æ·ÃÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
 - ÀÌ ¾àÀº ÇÁ·ÎÇÊ·»±Û¸®ÄÝÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. 
 - ÀÌ ¾àÀº Ä¡¿À¾ÆÈ²»ê³ªÆ®·ýÀÌ ÇÔÀ¯µÇ¾î ÀÖÀ¸¹Ç·Î ¾ÆÈ²»ê¾Æ³ªÇʶô½Ã¿Í °°Àº ¾Ë·¹¸£±â¸¦ ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¸ç,ÀϺΠ°¨¼ö¼º ȯÀÚ¿¡¼´Â »ý¸íÀ» À§ÇùÇÒ Á¤µµ ¶Ç´Â À̺¸´Ù ¾àÇÑ Ãµ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ÀÏ¹Ý »ç¶÷¿¡¼ÀÇ ¾ÆÈ²»ê °¨¼ö¼º¿¡ ´ëÇÑ ÃѰýÀûÀÎ ºóµµ´Â ¾Ë·ÁÁöÁö ¾Ê¾ÒÀ¸³ª ³·Àº °ÍÀ¸·Î º¸ÀÌ¸ç ¾ÆÈ²»ê °¨¼ö¼ºÀº ºñõ½Ä ȯÀÚº¸´Ù õ½ÄȯÀÚ¿¡¼ ºó¹øÇÑ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
 
  | 
   
  
    
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      - ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ¹ßÁø, ¹ßÀû, Á¾Ã¢, °¡·Á¿ò µîÀÇ Áõ»óÀÌ ÀÖ´Â °æ¿ì¿¡´Â »ç¿ë À» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇÑ´Ù.
 - ÀÌ ¾àÀÇ »ç¿ëÀ¸·Î ȯºÎ¿¡ ¹«Á», ¹é¼± µîÀÇ ¹é¼±Áõ, ¿©µå¸§, ȳóÁõ»ó, Áö¼ÓÀûÀÎ Àڱذ¨, ¹ßÁø µîÀÇ Áõ»óÀÌ ÀÖ´Â °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç ¿Í »ó´ãÇÑ´Ù.
      
    
 
  | 
   
        
  
  
  
    
  
  
       	
  
  
   
    | Off-label Usage | 
    
      
	[Á¶È¸]    
     | 
   
     
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
  |  
     
   
  
    
       |  
      
        
          
            
                | Á¤º¸¿ä¾à |         
             
           
         | 
             	    
       |  
      | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
     
   
  
    
       |  
      
        
          
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |         
             
           
         | 
             	    
       |  
      | 	 |  
     
   
  
    
       |  
      
        
          
            
                | Á¦Ç°Á¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
   
  
    
       |  
      
        
          
            
                | º¹¾àÁ¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        	
					  
					
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
     
   
  
    
       |  
      
        
          
            
                | ½É»çÁ¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
     
  
    
       |  
      
        
          
            
                | ÇмúÁ¤º¸ |          
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Camphor¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
Dexamethasone¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
Diphenhydramine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
L-Menthol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Crotamiton¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching.
  Dexamethasone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. This results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
  Dibucaine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
  Diphenhydramine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Diphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. 
     | 
   
  
   
    | Pharmacology | 
     
       Crotamiton¿¡ ´ëÇÑ Pharmacology Á¤º¸ Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism.
  Dexamethasone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dexamethasone and its derivatives, dexamethasone sodium phosphate and dexamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties and ability to penetrate the CNS, dexamethasone is used alone to manage cerebral edema and with tobramycin to treat corticosteroid-responsive inflammatory ocular conditions.
  Dibucaine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dibucaine is an amide-type local anesthetic, similar to lidocaine.
  Diphenhydramine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, diphenhydramine competes with free histamine for binding at HA-receptor sites. Diphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of diphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown. 
     | 
   
  
   
    | Metabolism | 
    
       Crotamiton¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
  Dexamethasone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
  Dibucaine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2D6 (CYP2D6)Cholinesterase
  Diphenhydramine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)Cytochrome P450 3A4 (CYP3A4) 
     | 
   
  
   
    | Protein Binding | 
    
       Crotamiton¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
  Dexamethasone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 70%
  Dibucaine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
  Diphenhydramine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 98 to 99% 
     | 
   
  
   
    | Half-life | 
    
       Crotamiton¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
  Dexamethasone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 36-54 hours
  Dibucaine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
  Diphenhydramine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-4 hours 
     | 
   
  
   
    | Absorption | 
    
       Crotamiton¿¡ ´ëÇÑ Absorption Á¤º¸ 10 % absorbed when applied locally.
  Dexamethasone¿¡ ´ëÇÑ Absorption Á¤º¸ 80-90%
  Dibucaine¿¡ ´ëÇÑ Absorption Á¤º¸ In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
  Diphenhydramine¿¡ ´ëÇÑ Absorption Á¤º¸ Quickly absorbed with maximum activity occurring in approximately one hour. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       Dexamethasone acetateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ´ë»çÈ¿°ú Áö¼Ó½Ã°£ : 72½Ã°£±îÁö Áö¼ÓµÉ ¼ö ÀÖ´Ù. Acetate´Â ÀÛ¿ë ¹ßÇö ½Ã°£À» ÃËÁø½ÃŲ Àå½Ã°£ Áö¼ÓÇü repository Á¦Á¦ÀÌ´Ù.
	
 - ´ë»ç : °£¿¡¼ ´ë»ç
	
 - ¹Ý°¨±â 
	
		-  Á¤»ó ½Å±â´É : 1.8¡3.5½Ã°£
		
 -  »ý¸®Àû ¹Ý°¨±â : 36¡54½Ã°£
	
  
	 - ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£
	
		-  °æ±¸ : 1¡2½Ã°£ À̳»
		
 -  ±ÙÀ°ÁÖ»ç : 8½Ã°£ À̳»
	
  
	 - ¼Ò½Ç : ´¢³ª º¯À¸·Î ¹è¼³
  
 Dibucaine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ÀÛ¿ë¹ßÇö½Ã°£ : 15ºÐ À̳»
 
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 2-4 ½Ã°£
 
 - Èí¼ö : ¼Õ»óµÇÁö ¾ÊÀº ÇǺο¡ Àû¿ë½Ã Èí¼ö´Â ¸Å¿ì ÀûÁö¸¸, Á¡¸·À̳ª ¼Õ»óµÈ ÇǺηκÎÅÍ´Â Àß Èí¼öµÈ´Ù.
   
 Diphenhydramine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÃÖ°í ÁøÁ¤ È¿°ú : 1-3 ½Ã°£
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 4-7 ½Ã°£
	
 - Èí¼ö : ÃÊȸÅë°úÈ¿°ú°¡ ÀÖ¾î¼ 40 - 60 % Á¤µµ°¡ Àü½Å¼øÈ¯À¸·Î µé¾î°¨
	
 - ´ë»ç : ´ëºÎºÐ °£´ë»ç, ÀϺδ Æó¿Í ½ÅÀå¿¡¼µµ ´ë»ç
	
 - ´Ü¹é°áÇÕ : 78%
	
 - ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : 2-4 ½Ã°£
 
  
 L-mentholÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ¼Ò½Ç : Èí¼öµÈ ¾à¹°Àº glucuronide Æ÷ÇÕü·Î¼ ¼Òº¯ ¹× ´ãÁóÀ» ÅëÇØ ¹è¼³µÈ´Ù.
  
     | 
   
  
   
    | Biotransformation | 
    
       Crotamiton¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
  Dexamethasone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
  Dibucaine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Primarily hepatic.
  Diphenhydramine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic and renal 
     | 
   
  
   
    | Toxicity | 
    
       Crotamiton¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
  Dexamethasone¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.
  Dibucaine¿¡ ´ëÇÑ Toxicity Á¤º¸ Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
  Diphenhydramine¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=500 mg/kg (orally in rats). Considerable overdosage can lead to myocardial infarction (heart attack), serious ventricular dysrhythmias, coma and death. 
     | 
   
  
   
    | Drug Interactions | 
    
       Crotamiton¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acetohexamide	The beta-blocker decreases the symptoms of hypoglycemiaChlorpropamide	The beta-blocker decreases the symptoms of hypoglycemiaCimetidine	Cimetidine increases the effect of the beta-blockerClonidine	Increased hypertension when clonidine stoppedDisopyramide	The beta-blocker increases toxicity of disopyramideGliclazide	The beta-blocker decreases the symptoms of hypoglycemiaGlipizide	The beta-blocker decreases the symptoms of hypoglycemiaGlisoxepide	The beta-blocker decreases the symptoms of hypoglycemiaGlibenclamide	The beta-blocker decreases the symptoms of hypoglycemiaGlycodiazine	The beta-blocker decreases the symptoms of hypoglycemiaInsulin	The beta-blocker decreases the symptoms of hypoglycemiaLidocaine	The beta-blocker increases the effect and toxicity of lidocainePropafenone	Propafenone increases the effect of beta-blockerRepaglinide	The beta-blocker decreases the symptoms of hypoglycemiaRifampin	Rifampin decreases the effect of the metabolized beta-blockerTelithromycin	Telithromycin may possibly increase metoprolol effectTolazamide	The beta-blocker decreases the symptoms of hypoglycemiaTolbutamide	The beta-blocker decreases the symptoms of hypoglycemiaAmobarbital	The barbiturate decreases the effect of metabolized beta-blockerAprobarbital	The barbiturate decreases the effect of metabolized beta-blockerButalbital	The barbiturate decreases the effect of metabolized beta-blockerButabarbital	The barbiturate decreases the effect of metabolized beta-blockerButethal	The barbiturate decreases the effect of metabolized beta-blockerDihydroquinidine barbiturate	The barbiturate decreases the effect of metabolized beta-blockerHeptabarbital	The barbiturate decreases the effect of metabolized beta-blockerHexobarbital	The barbiturate decreases the effect of metabolized beta-blockerMethohexital	The barbiturate decreases the effect of metabolized beta-blockerMethylphenobarbital	The barbiturate decreases the effect of metabolized beta-blockerPentobarbital	The barbiturate decreases the effect of metabolized beta-blockerPhenobarbital	The barbiturate decreases the effect of metabolized beta-blockerPrimidone	The barbiturate decreases the effect of metabolized beta-blockerQuinidine barbiturate	The barbiturate decreases the effect of metabolized beta-blockerSecobarbital	The barbiturate decreases the effect of metabolized beta-blockerTalbutal	The barbiturate decreases the effect of metabolized beta-blockerCitalopram	The SSRI increases the effect of the beta-blockerEscitalopram	The SSRI increases the effect of the beta-blockerFluoxetine	The SSRI increases the effect of the beta-blockerSertraline	The SSRI increases the effect of the beta-blockerParoxetine	The SSRI increases the effect of the beta-blockerDihydroergotamine	Ischemia with risk of gangreneDihydroergotoxine	Ischemia with risk of gangreneErgonovine	Ischemia with risk of gangreneErgotamine	Ischemia with risk of gangreneMethysergide	Ischemia with risk of gangreneVerapamil	Increased effect of both drugsHydralazine	Increased effect of both drugsDiltiazem	Increased risk of bradycardiaEpinephrine	Hypertension, then bradycardiaFenoterol	AntagonismFormoterol	AntagonismIsoproterenol	AntagonismOrciprenaline	AntagonismPirbuterol	AntagonismPrazosin	Risk of hypotension at the beginning of therapyProcaterol	AntagonismSalbutamol	AntagonismSalmeterol	AntagonismTerbutaline	AntagonismIbuprofen	Risk of inhibition of renal prostaglandinsIndomethacin	Risk of inhibition of renal prostaglandinsPiroxicam	Risk of inhibition of renal prostaglandins
  Dexamethasone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Ambenonium	The corticosteroid decreases the effect of anticholinesterasesAminoglutethimide	Aminogluthetimide decreases the effect of dexamethasoneAmobarbital	The barbiturate decreases the effect of the corticosteroidAnisindione	The corticosteroid alters the anticoagulant effectAprepitant	Aprepitant increases the effect and toxicity of dexamethasoneAprobarbital	The barbiturate decreases the effect of the corticosteroidAspirin	The corticosteroid decreases the effect of salicylatesButabarbital	The barbiturate decreases the effect of the corticosteroidButalbital	The barbiturate decreases the effect of the corticosteroidButethal	The barbiturate decreases the effect of the corticosteroidDicumarol	The corticosteroid alters the anticoagulant effectDihydroquinidine barbiturate	The barbiturate decreases the effect of the corticosteroidEdrophonium	The corticosteroid decreases the effect of anticholinesterasesEthotoin	The enzyme inducer decreases the effect of the corticosteroidFosphenytoin	The enzyme inducer decreases the effect of the corticosteroidHeptabarbital	The barbiturate decreases the effect of the corticosteroidHexobarbital	The barbiturate decreases the effect of the corticosteroidImatinib	Decreases levels of imatinibMephenytoin	The enzyme inducer decreases the effect of the corticosteroidMethohexital	The barbiturate decreases the effect of the corticosteroidMethylphenobarbital	The barbiturate decreases the effect of the corticosteroidMidodrine	Increased arterial pressureNeostigmine	The corticosteroid decreases the effect of anticholinesterasesPentobarbital	The barbiturate decreases the effect of the corticosteroidPhenobarbital	The barbiturate decreases the effect of the corticosteroidPhenytoin	The enzyme inducer decreases the effect of the corticosteroidPrimidone	The barbiturate decreases the effect of the corticosteroidPyridostigmine	The corticosteroid decreases the effect of anticholinesterasesQuinidine barbiturate	The barbiturate decreases the effect of the corticosteroidRifampin	The enzyme inducer decreases the effect of the corticosteroidSecobarbital	The barbiturate decreases the effect of the corticosteroidSunitinib	Possible decrease in sunitinib levelsTalbutal	The barbiturate decreases the effect of the corticosteroidWarfarin	The corticosteroid alters the anticoagulant effectBismuth	The corticosteroid decreases the effect of salicylatesAcenocoumarol	The corticosteroid alters the anticoagulant effectSalicylate-magnesium	The corticosteroid decreases the effect of salicylatesSalsalate	The corticosteroid decreases the effect of salicylates
  Dibucaine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Methotrexate	The NSAID increases the effect and toxicity of methotrexateLithium	The NSAID increases serum levels of lithiumAcenocoumarol	The NSAID increases the anticoagulant effect
  Diphenhydramine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Atomoxetine	The CYP2D6 inhibitor could increases the effect and toxicity of atomoxetineDonepezil	Possible antagonism of actionGalantamine	Possible antagonism of actionMesoridazine	Increased risk of cardiotoxicity and arrhythmiasRivastigmine	Possible antagonism of actionThioridazine	Increased risk of cardiotoxicity and arrhythmias 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Crotamiton¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
  Dexamethasone¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food to reduce irritation.Avoid taking with grapefruit juice.
  Diphenhydramine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take with food. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Crotamiton¿¡ ´ëÇÑ Description Á¤º¸ Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.
  Dexamethasone¿¡ ´ëÇÑ Description Á¤º¸ An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]
  Dibucaine¿¡ ´ëÇÑ Description Á¤º¸ A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
  Diphenhydramine¿¡ ´ëÇÑ Description Á¤º¸ A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects. 
     | 
   
  
   
    | Dosage Form | 
    
       Crotamiton¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream	Topical
  Dexamethasone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Elixir	OralLiquid	IntramuscularLiquid	IntravenousLiquid	OralOintment	OphthalmicSolution	IntravenousSolution	OphthalmicSolution / drops	OphthalmicTablet	Oral
  Dibucaine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Ointment	Rectal
  Diphenhydramine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule	OralCream	TopicalElixir	OralLiquid	IntramuscularLiquid	IntravenousLiquid	OralLozenge	OralStrip	OralSyrup	OralTablet	OralTablet, chewable	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Crotamiton¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiparasitic AgentsAntipruriticsPesticidesScabicides
  Dexamethasone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic AgentsAnti-inflammatory AgentsAntiemeticsAntineoplastic Agents, HormonalGlucocorticoids
  Dibucaine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anesthetics, Local
  Diphenhydramine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnestheticsAnesthetics, LocalAnti-Allergic AgentsAntidyskineticsAntiemeticsAntiparkinson AgentsAntipruriticsAntitussivesEthanolamine DerivativesHistamine H1 AntagonistsHypnotics and Sedatives 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Crotamiton¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(C(=O)C=CC)C1=CC=CC=C1C
  Dexamethasone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
  Dibucaine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
  Diphenhydramine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Crotamiton¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(C(=O)\C=C\C)C1=CC=CC=C1C
  Dexamethasone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
  Dibucaine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
  Diphenhydramine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1 
     | 
   
  
   
    | InChI Identifier | 
    
       Crotamiton¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3
  Dexamethasone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
  Dibucaine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)/f/h21H
  Diphenhydramine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Crotamiton¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-ethyl-N-(2-methylphenyl)but-2-enamide
  Dexamethasone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
  Dibucaine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-butoxy-N-(2-diethylaminoethyl)quinoline-4-carboxamide
  Diphenhydramine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-[di(phenyl)methoxy]-N,N-dimethylethanamine 
     | 
   
  
   
    | Drug-Induced Toxicity Related Proteins | 
    
      DEXAMETHASONE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Brain-cadherin (BR-cadherin) Drug:dexamethasone Toxicity:osteoblast differentiation.  [¹Ù·Î°¡±â] Replated Protein:Glucocorticoid-induced leucine zipper (GILZ) Drug:dexamethasone Toxicity:apoptosis.  [¹Ù·Î°¡±â] Replated Protein:Signal transducer and activator of transcription 3 Drug:dexamethasone Toxicity:apoptosis.  [¹Ù·Î°¡±â] Replated Protein:Heme oxygenase 1 Drug:dexamethasone Toxicity:oxidative injury.  [¹Ù·Î°¡±â] Replated Protein:Alkaline phosphatase Drug:dexamethasone Toxicity:osteoblast differentiation.  [¹Ù·Î°¡±â] Replated Protein:Interleukin-6  Drug:dexamethasone Toxicity:apoptosis.  [¹Ù·Î°¡±â] Replated Protein:Ornithine decarboxylase  Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers.  [¹Ù·Î°¡±â] Replated Protein:Aromatic-L-amino-acid decarboxylase  Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers.  [¹Ù·Î°¡±â] Replated Protein:Interleukin-4  Drug:dexamethasone Toxicity:dexamethasone-induced differentiation of mouse myeloid leukemia cells.  [¹Ù·Î°¡±â] Replated Protein:Gastrin Drug:dexamethasone Toxicity:pathogenesis of peptic ulcers.  [¹Ù·Î°¡±â] Replated Protein:Interleukin-4  Drug:dexamethasone Toxicity:dexamethasone-induced differentiation of mouse myeloid leukemia cells.  [¹Ù·Î°¡±â] Replated Protein:Cadherin-11  Drug:dexamethasone Toxicity:osteoblast differentiation.  [¹Ù·Î°¡±â] Replated Protein:Haptoglobin  Drug:dexamethasone Toxicity:hepatic lipidosis(fatty liver).  [¹Ù·Î°¡±â] Replated Protein:Interferon alpha-7  Drug:dexamethasone Toxicity:apoptosis.  [¹Ù·Î°¡±â] Replated Protein:C-jun-amino-terminal kinase-interacting protein  Drug:dexamethasone Toxicity:apoptosis of multiple myeloma cells.  [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase Drug:dexamethasone Toxicity:Dex-induced apoptosis.  [¹Ù·Î°¡±â] Replated Protein:Cadherin-4  Drug:dexamethasone Toxicity:osteoblast differentiation.  [¹Ù·Î°¡±â] Replated Protein:Glucose transporter 4 Drug:dexamethasone Toxicity:cushing's syndrome.  [¹Ù·Î°¡±â] Replated Protein:Nuclear factor NF-kappa-B Drug:dexamethasone Toxicity:pulmonary inflammation.  [¹Ù·Î°¡±â] Replated Protein:Signal transducer and activator of transcription 3 Drug:dexamethasone Toxicity:oxidative injury such as endotoxins and heme.  [¹Ù·Î°¡±â] Replated Protein:Thrombomodulin  Drug:dexamethasone  Toxicity:deep venous thrombosis (DVT).  [¹Ù·Î°¡±â] Replated Protein:Islet amyloid polypeptide Drug:dexamethasone  Toxicity:marked stimulatory effect.  [¹Ù·Î°¡±â] 
     | 
   
    
  |  
     
     
  
    
       |  
      
        
          
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ |           
             
           
         | 
             	  
       |  
       |  
     
         
 
     | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2017-07-12
              
 
              - 
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
  
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. DEXAMETHASONE ACETATE[GGT Increase][Composite Activity](Score)  NA(Marginal)  0(Active)  0[Alkaline Phosphatase Increase](Activity Score)  NA(Number of Rpts)  NA(Index value)  NA[SGOT Increase](Activity Score)  NA(Number of Rpts)  NA(Index value)  NA[SGPT Increase](Activity Score)  NA(Number of Rpts)  NA(Index value)  NA[LDH Increase](Activity Score)  NA(Number of Rpts)  NA(Index value)  NA[GGT Increase](Activity Score)  NA(Number of Rpts)  NA(Index value)  NA
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
 |  
                           
                         | 
                       
                      | 
                   |